Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma

Wei-Lin Liu1, Ming Gao, Kai-Yuan Tzen

  • 1Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.

Oncotarget
|July 9, 2014
PubMed

Insights

Combining BKM120, a PI3K inhibitor, with radiotherapy enhances liver cancer cell sensitivity to radiation. This approach increases cancer cell death and reduces DNA repair, suggesting a promising new strategy for hepatocellular carcinoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Radiotherapy for hepatocellular carcinoma (HCC) shows limited efficacy.
  • The phosphatidylinositol 3-kinase (PI3K)/Akt pathway promotes cancer cell survival and radiation resistance.
  • Elevated PI3K/Akt activity is linked to poorer outcomes in irradiated cancer cells.

Purpose of the Study:

  • To investigate if inhibiting PI3K/Akt activity with BKM120 sensitizes liver cancer cells to irradiation.
  • To evaluate the synergistic effects of BKM120 and radiotherapy in vitro and in vivo.

Main Methods:

  • Hepatocellular carcinoma cell lines (Huh7, BNL) were treated with BKM120 and irradiation.
  • In vivo studies involved Balb/c mice with BNL xenografts receiving BKM120 and/or radiotherapy.
  • Apoptotic markers, DNA double-strand break repair, and Akt phosphorylation were assessed.

Main Results:

  • BKM120 enhanced radiation-induced cancer cell killing and apoptosis.
  • The combination suppressed the repair of radiation-induced DNA double-strand breaks.
  • BKM120 inhibited radiation-induced Akt phosphorylation and improved tumor suppression in vivo.
  • Rapamycin further enhanced radiosensitivity in BKM120-treated cells.

Conclusions:

  • The combination of BKM120 and irradiation demonstrates synergistic effects in HCC.
  • This combination likely enhances apoptosis and inhibits DNA repair by targeting the PI3K/Akt pathway.
  • BKM120 and radiotherapy represent a potential clinical strategy for HCC treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K